Format

Send to

Choose Destination
Curr Opin Investig Drugs. 2003 Jun;4(6):675-85.

Telomerase inhibitors in cancer therapy: current status and future directions.

Author information

1
Cancer Research UK Biomolecular Structure Group, School of Pharmacy, University of London, 29-39 Brunswick Square, London, WC1N 1AX, UK.

Abstract

The ends of chromosomes (telomeres) are subject to progressive shortening in normal somatic cells, leading ultimately to irreversible growth arrest. In contrast, telomeres in all cancer cells are stabilized in length and effectively immortalized by the enzyme telomerase, which catalyzes the synthesis of telomeric DNA repeats. Several strategies have been devised for the inhibition of telomerase in the hope that this will result in anticancer effects. The principal approaches of catalytic inhibitors, antisense to the template, and folding of the DNA substrate, are reviewed and critically evaluated for their potential in anticancer therapy.

PMID:
12901225
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center